MRSN - Mersana Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

92.84M

Cash

183.1M

Avg Qtr Burn

-43.13M

Short % of Float

12.72%

Insider Ownership

1.36%

Institutional Own.

99.55%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
XMT-2056 (HER2 ADC) Details Cancer, Non-small cell lung carcinoma, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XMT-1660 (B7-H4 ADC) Details Ovarian cancer, Cancer, Endometrial cancer, Breast cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Upifitamab Risodotin (UpRi) (XMT-1536) (NAPi2b ADC) Details Ovarian cancer, Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Upifitamab Risodotin (UpRi) (XMT-1536) (NAPi2b ADC) Details Ovarian cancer, Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Upifitamab Risodotin (UpRi) (XMT-1536) (NAPi2b ADC) Details Ovarian cancer, Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XMT-1592 (NaPi2b antigen) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.